LifeCell
AbbVie is a global biopharmaceutical company that discovers, develops, and commercializes prescription medicines across immunology, oncology, neuroscience, eye care, and aesthetics, serving healthcare providers and patients in 180+ countries.
- Company typePublic
- Founded2013
- HeadquartersBridgewater, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What LifeCell does
AbbVie is a global publicly traded biopharmaceutical company (NYSE: ABBV) headquartered in North Chicago, Illinois, founded in 2013 as a spin-off from Abbott Laboratories. The company discovers, develops, and commercializes prescription pharmaceutical products across five core therapeutic areas: immunology, oncology, neuroscience, eye care, and aesthetics. Its innovation platform spans small molecules, biologics, antibody-drug conjugates (ADCs), precision medicine, and genomics-based approaches, with 75% of its medicines described as first-in-kind. The aesthetics franchise is operated through the wholly-owned Allergan Aesthetics subsidiary, acquired in 2020.
AbbVie generates revenue primarily through prescription pharmaceutical product sales distributed globally across 180+ countries and territories via direct commercial operations, hospital systems, retail pharmacies, and patient assistance programs. Its go-to-market relies on pharmaceutical sales representatives targeting physicians, hospitals, and clinics, with distribution requiring physician authorization. The company supplements its proprietary R&D with 250+ active external innovation partnerships and a corporate venture arm (AbbVie Ventures) to source pipeline assets. A U.S. patient assistance program (My AbbVie) provided free medicine to 210K+ qualifying patients in 2025.
The company operates at significant scale with approximately 57,000 employees globally, 56% of whom are women as of December 2025. It reported FY2025 revenue of $56.3 billion USD, supports 250+ active external innovation partnerships, and has achieved a 39% reduction in absolute Scope 1 and 2 GHG emissions versus a 2021 baseline. Branding and cause-marketing initiatives include partnerships with the Chicago Cubs and Major League Baseball, supporting patient and healthcare provider engagement across global markets.
LifeCell firmographics
Firmographics- Name
- LifeCell
- Legal name
- AbbVie Inc.
- Website
- https://lifecell.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- AbbVie is a global biopharmaceutical company that discovers, develops, and commercializes prescription medicines across immunology, oncology, neuroscience, eye care, and aesthetics, serving healthcare providers and patients in 180+ countries.
- Ownership category
- akta.pro rank
LifeCell industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
- akta.pro secondary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where LifeCell is headquartered
LocationHeadquarters
- HQ city
- Bridgewater
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
LifeCell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Pharmaceutical Product Sales: AbbVie generates revenue primarily through the sale of prescription pharmaceutical products across therapeutic areas including immunology, oncology, neuroscience, eye care, and aesthetics. Products are distributed through pharmacy channels globally with revenue driven by volume and pricing across government and commercial payors.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Patient Assistance Programs |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
LifeCell product offering
Product offeringCore offering
LifeCell discovers, develops, manufactures, and commercializes prescription biopharmaceutical medicines across therapeutic areas including immunology, oncology, neuroscience, eye care, and aesthetics. Products are distributed globally through prescription-based pharmaceutical channels to healthcare providers, hospitals, and retail pharmacies in 180+ countries, with patient assistance programs supporting access for qualifying patients.
Differentiator
Problem solved
Functional benefit
Brands
- Allergan Aesthetics: Medical aesthetics and cosmetic products division of AbbVie
Products and services
- Allergan Aesthetics Medical aesthetics and cosmetic products division acquired in 2020, addressing the aesthetics therapeutic area within LifeCell's portfolio.
- Immunology Therapeutics Prescription pharmaceutical products for the treatment of autoimmune and immunological diseases.
- Oncology Therapeutics Prescription pharmaceutical products for the treatment of cancer, including next-generation antibody-drug conjugate (ADC) technology for targeted cancer treatment.
- Neuroscience Therapeutics Prescription pharmaceutical products for the treatment of neurological disorders.
- Eye Care Therapeutics Prescription pharmaceutical products for the treatment of eye conditions.
- Contract Manufacturing Services Pharmaceutical contract manufacturing services offered to enterprise customers for the production of drug products.
Quantifiable outcome
- 180+ countries and territories served
- +2 more outcomes
Companies that use LifeCell
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
LifeCell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
LifeCell partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- 250+ External Innovation PartnerscoreAbbVie maintains 250+ active external innovation partnerships for conducting groundbreaking science to discover and develop transformational medicines across therapeutic areas.
- Chicago CubsminorBrand partnership with Chicago Cubs Major League Baseball team for marketing and brand awareness initiatives.
- Major League BaseballminorBrand partnership with Major League Baseball organization for marketing and brand awareness initiatives.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
LifeCell competitors and assessment
Company assessmentDirect peers
- Bristol-Myers Squibb: Direct peer in immunology and oncology with global branded Rx model — competes for the same immunology patient pool and faces similar IRA/pricing dynamics.
- Roche: Swiss biopharma with major oncology, immunology, and ophthalmology franchises — directly comparable in biologics depth, ophthalmology presence, and global commercial reach.
- Pfizer: Global biopharmaceutical company of comparable scale with diversified Rx franchises across oncology, immunology, vaccines, and primary care — overlapping therapeutic areas, global commercial footprint, and branded-innovator business model.
- Johnson & Johnson (Innovative Medicine): Diversified pharma major with immunology (Stelara, Tremfya), oncology, and neuroscience assets — directly competitive in immunology and oncology, with a similar global Rx distribution model.
- Merck & Co. Large-cap biopharma with leading oncology and vaccines franchises and a global Rx commercial model — comparable scale, therapeutic-area diversification, and innovator-driven pipeline.
- Eli Lilly: Innovator pharma peer with overlapping immunology, oncology, and neuroscience exposure and a comparable branded biologics / specialty commercial model.
- Novartis: Global branded-innovator pharma with overlapping presence in immunology, oncology, and ophthalmology — similar enterprise sales model and biosimilar exposure.
- Sanofi: Diversified European pharma with immunology (Dupixent), vaccines, and rare-disease franchises — directly competitive in immunology and operates a comparable global Rx model.
- GSK: Global biopharma with branded Rx across specialty medicines, vaccines, and HIV — comparable scale, therapeutic breadth, and exposure to pricing reform in U.S. and Europe.
- Amgen: Biologics-heavy innovator peer with leading presence in immunology and oncology — directly comparable in branded biologic commercial model and biosimilar competitive dynamics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
LifeCell social profiles
Digital presenceLifeCell financial estimates
Financial estimateRevenue estimate
Valuation estimate
LifeCell leadership team
Management profileNumber of profiles
LifeCell subsidiaries and ownership
Company hierarchySubsidiaries1 record
LifeCell funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LifeCell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LifeCell
What does LifeCell do?
LifeCell discovers, develops, manufactures, and commercializes prescription biopharmaceutical medicines across therapeutic areas including immunology, oncology, neuroscience, eye care, and aesthetics. Products are distributed globally through prescription-based pharmaceutical channels to healthcare providers, hospitals, and retail pharmacies in 180+ countries, with patient assistance programs supporting access for qualifying patients.
Is LifeCell a public or private company?
LifeCell is a public company. It is classified as public and is currently operating.
When was LifeCell founded?
LifeCell was founded in 2013. It employs 501 to 1,000 people.
Where is LifeCell based?
LifeCell is headquartered in Bridgewater, United States, in the North America region.
How does LifeCell make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are LifeCell's main competitors?
Direct peers on record are Bristol-Myers Squibb, Roche, Pfizer, Johnson & Johnson (Innovative Medicine), Merck & Co., Eli Lilly, Novartis, Sanofi, GSK and Amgen.
Does LifeCell have an API?
No public API is recorded for LifeCell.
What industry is LifeCell in?
LifeCell's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.